Top
pipeline-stages-03.png
  • ASN100

    Our lead program, ASN100, is being studied to prevent hospital-acquired Staphylococcus aureus pneumonia in mechanically-ventilated patients who are heavily-colonized with Staphylococcus aureus.

    Learn more

  • ASN200

    Arsanis is studying ASN200 to potentially combat infections caused by multi-drug resistant strains of the Gram-negative pathogen Escherichia coli.

    Learn more

  • ASN300

    Arsanis is developing ASN300 to address infections caused by multi-drug resistant strains of the Gram-negative pathogen Klebsiella pneumoniae.

    Learn more

  • ASN400

    The ASN400 program is currently in the discovery phase and is designed to counteract important virulence mechanisms of Streptococcus pneumoniae.

    Learn more

  • ASN500

    The ASN500 program, comprised of highly potent mAbs targeting RSV, is currently in the discovery phase. Arsanis received a $9.3 million grant from the Bill & Melinda Gates Foundation to take an initial RSV candidate through to IND filing.

    Learn more